Zevra Therapeutics Inc (ZVRA)
Zevra Therapeutics Inc. is a commercial-stage healthcare company focused on developing and commercializing treatments for rare diseases in the United States. Using its Ligand Activated Technology platform, the company is advancing a pipeline that includes KP1077, with Phase 3 studies underway for idiopathic hypersomnia and narcolepsy, as well as Celiprolol, which is being studied in Phase 3 for vascular Ehlers-Danlos syndrome. Zevra also markets AZSTARYS for attention deficit hyperactivity disorder in patients six years and older, OLPRUVA for urea cycle disorders, and MIPLYFFA for Niemann-Pick disease type C. The company has collaboration and licensing arrangements with Commave Therapeutics SA, Acer, and Relief Therapeutics related to certain development and commercialization rights. Formerly known as KemPharm, Inc., Zevra was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ZVRA
|
$12.99
|
5.2% Upside
|
Fair
|
$27.89
|
125.8% Upside
|
Bargain
|
Great
|
—
|
—
|
—
|
0.0%
|
August 18, 2026
|
6.2x
|
3.6x
|
6.0x
|
711.2 M
|
495.3 M
|
0.2%
|
92.9%
|
5.3
|
—
|
10.3%
|
